Welcome to our dedicated page for Telomir Pharmaceuticals SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Telomir Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Telomir Pharmaceuticals's regulatory disclosures and financial reporting.
Telomir Pharmaceuticals, Inc. CEO and Chairman Erez Aminov reported changes to his stock option awards. On May 21, 2026, he agreed to cancel previously granted options for 2,000,000 shares of common stock at a $2.10 exercise price and 1,960,170 shares at $5.02, both through dispositions to the issuer. In exchange, he received fully exercisable new options covering the same share amounts at a lower $1.30 exercise price, with expirations in 2036. The filing also shows he holds 7,319,710 common shares directly after these transactions, and it does not report any open‑market purchases or sales.
Telomir Pharmaceuticals director Whalen Matthew Pratt reported an option restructuring. He agreed to cancel 25,000 incentive stock options with a $5.02 exercise price in exchange for 25,000 new options with a lower $1.30 exercise price, expiring on May 21, 2036. Following these transactions, he holds 25,000 incentive stock options that are fully exercisable.
Telomir Pharmaceuticals director Edward Clouston MacPherson restructured his stock options with no net change in option count. He agreed to cancel an existing option for 25,000 shares of common stock with a $5.02 exercise price and an expiration on August 27, 2034. In exchange, he received a new option for 25,000 shares at a lower exercise price of $1.30, expiring on May 21, 2036. These are incentive stock options granted as compensation, not open-market share purchases or sales, and he now holds 25,000 options directly following the transaction.
Telomir Pharmaceuticals, Inc. director Matthew Paul Del Giudice reported a restructuring of his stock options with no net change in option count. He agreed to cancel 25,000 fully exercisable incentive stock options for common stock with a $5.02 exercise price and a August 27, 2034 expiration, as a disposition back to the issuer.
In exchange, he received a new grant of 25,000 incentive stock options for common stock with a lower exercise price of $1.30 per share and a May 21, 2036 expiration. Following these transactions, he holds 25,000 stock options directly, and no common shares were bought or sold in the market.
Telomir Pharmaceuticals, Inc. filed an 8-K describing a press release about a new peer-reviewed preclinical study of its lead candidate Telomir-1 (Telomir-Zn) in Wilson’s disease. The study, published in Advances in Redox Research, used cellular systems and an ATP7B-deficient zebrafish model.
Telomir-Zn showed dose-dependent benefits across multiple endpoints, including reduced copper-associated oxidative stress, lower hepatic copper burden, improved liver injury biomarkers such as ALT, AST and bilirubin, attenuated intracellular calcium dysregulation, better locomotor performance, reduced hepatorenal tissue degeneration, and improved survival.
This is Telomir-Zn’s first peer-reviewed publication in Wilson’s disease and adds independently validated preclinical data supporting its mechanism of modulating intracellular copper and redox pathways. The company notes these pathways are also relevant to its Telomir-Zn program in Triple-Negative Breast Cancer, which has FDA IND clearance for a Phase 1/2 trial.
Telomir Pharmaceuticals reported a Q1 2026 net loss of $0.99 million with no revenue, reflecting its early-stage biotech focus on Telomir-1 (Telomir-Zn) for cancer and age-related diseases. Operating costs were $1.04 million, with general and administrative expenses falling sharply year over year as prior stock-based compensation stepped down, while research and development rose modestly as preclinical and clinical work progressed.
Cash was $5.6 million as of March 31, 2026 after using about $1.8 million in operating cash during the quarter, leaving stockholders’ equity of roughly $5.0 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months without new capital. After quarter-end, Telomir closed its merger with related-party TELI Pharmaceuticals, issuing 34,389,710 restricted shares and securing a $1.0 million cash contribution plus a binding commitment for up to an additional $4.0 million tied to Telomir-1 development milestones. A small at-the-market sale added about $6,000 of proceeds.
Telomir Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir‑Zn, the company’s lead product candidate, to treat advanced or metastatic triple‑negative breast cancer.
The company plans a first‑in‑human Phase 1/2 trial starting in the first half of 2026, enrolling about 76 patients. Phase 1 will focus on safety, tolerability, dose‑limiting toxicities, pharmacokinetics, pharmacodynamics, and early antitumor activity to determine the recommended Phase 2 dose. Phase 2 will assess preliminary efficacy, with objective response rate as the primary endpoint and duration of response, progression‑free survival, overall survival, and safety as key secondary endpoints.
The trial will feature an extensive translational biomarker program to study epigenetic regulation, gene expression, histone modification, and telomere‑related biology, aiming to link target engagement and biomarker changes with clinical outcomes in triple‑negative breast cancer.
Telomir Pharmaceuticals CEO and Chairman Erez Aminov reported a restructuring-related share exchange rather than an open-market trade. He is shown with 7,319,710 shares of common stock at a reported value of $1.3700 per share following the transaction. A footnote explains these Telomir shares were issued to him in exchange for his shares of TELI Pharmaceuticals, Inc. in connection with Telomir’s acquisition of TELI, so the filing reflects how his prior TELI ownership converted into Telomir equity.
Telomir Pharmaceuticals completed its acquisition of TELI Pharmaceuticals, issuing 34,389,710 restricted shares of common stock to TELI’s former shareholders. The share count was based on an exchange ratio derived from independent third-party valuations of both companies.
At closing, Bayshore Trust contributed $1 million to Telomir and entered into an option to pay up to $4 million more for Telomir shares if milestones are met, including FDA acceptance of an Investigational New Drug application and initiation of a Phase 1/2 study for Telomir-1. The deal consolidates all global rights to Telomir-1 under Telomir, giving it full control over development and potential commercialization across major international markets.
Telomir Pharmaceuticals, Inc. reported that on March 30, 2026 it received a letter from the Nasdaq Capital Markets confirming the company is now in compliance with Nasdaq Listing Rule 5620(a) after holding its 2025 Annual Meeting of Shareholders. Nasdaq has determined the matter is closed, meaning Telomir’s listing status related to this meeting requirement is no longer in question.